mardi 22 septembre 2020


Wednesday, April 25th 2018 at 11:30am UTC

Promising first-in-class and potential medical breakthrough pipeline
projects presented at R&D Press Conference

  • 80 clinical and pre-clinical projects of which 65% have
    first-in-class and breakthrough potential
  • Highlight: First-in-class monoclonal antibody shows potential in
    multiple inflammatory diseases
  • 15 new medicines could potentially be approved by 2025 in
    immunology, CNS, oncology, respiratory and cardiometabolic diseases

INGELHEIM, Germany–(BUSINESS WIRE)– Family-owned pharmaceutical company Boehringer Ingelheim today presented
its latest pipeline updates at a Research & Development press conference
entitled ‘Transcending Disease Boundaries’, at its global headquarters
in Ingelheim, Germany. The company’s R&D strategy and current pipeline
has the potential to deliver 15 new medicines for approval by 2025
(probability adjusted). With a high percentage of first-in-class and
breakthrough potential drug candidates, Boehringer Ingelheim continues
the successful implementation of its R&D strategy.

Boehringer Ingelheim is committing more than €20 billion to Research &
Development for human pharmaceuticals by 2025. In the past four years,
the company received 14 regulatory approvals in several new indications,
including four new molecular entities and four breakthrough designations
by the US Food and Drug Administration.

“The most ambitious goal for researchers is to achieve a medical
breakthrough for patients from our over 80 clinical and pre-clinical
projects. Some 65% of our drug pipeline candidates already have
breakthrough and/or first-in-class potential, and we aim for even more”
said Dr Michel Pairet, Member of the Board of Managing Directors,
responsible for Boehringer Ingelheim’s Innovation Unit, “Transcending
disease boundaries is about looking at R&D with fresh eyes.”

To fulfil such aspirations, Boehringer Ingelheim embraces risks to dig
deep into the mechanisms of diseases, to integrate the latest scientific
and technological advances, and to work with the best partners to
discover and deliver new medicines.

“Our worldwide team of 8,000 scientists, medical doctors and other
contributors is truly motivated by our pipeline, its progress and what
this could mean for patients.” commented Dr Christopher Corsico, Chief
Medical Officer, Boehringer Ingelheim. “With ongoing work on a
first-in-class inhibitor targeting inflammatory skin and bowel diseases,
transformative oncology candidates, a promising schizophrenia prevention
strategy and major indications for two of our blockbusters, Ofev®
in lung fibrosis and Jardiance® in chronic kidney disease and
chronic heart failure, we look forward to bringing years of health and
improved quality of life to millions of people.”

To support and complement its own R&D, Boehringer Ingelheim is
increasing the emphasis on external collaborations and expanding the
community of innovation partners. The company currently works with over
70 innovative partners in universities, scientific institutions and
biotech companies.

“Our long-lasting relationships with our partners are built on respect,
empathy, trust and passion – values which foster an environment where
synergies are realized, resulting in the potential for faster and better
results.” said Dr Michel Pairet. “Our long-term, unwavering commitment
to researching and developing new medicines will bring the
transformative medicines that patients need.”

Highlights of Latest Boehringer Ingelheim Pipeline Progress

Immunology

In Immunology Boehringer Ingelheim’s IL-36 receptor inhibitor has the
potential to transform the standard-of-care for patients with
immune-mediated diseases.

BI 655130, a new biological entity and first-in-class IL-36 receptor
antibody, has shown strong efficacy in early clinical testing with a
single dose in patients affected by Generalized Pustular Psoriasis.
These results support a broad potential in multiple inflammatory
diseases.

Trials are underway in further immune-mediated diseases of the skin and
intestine including Palmo-Plantar Pustulosis, Ulcerative Colitis,
Crohn’s Disease, and other chronic inflammatory conditions.

Oncology

Boehringer Ingelheim is exploring therapies that target tumour cells
directly in pathways so far ‘undrugged’. In Immune Oncology, the
research teams are “turning up the heat on cancer” with therapies that
activate the abilities of the patient’s own immune system and by
bringing together smart and highly promising combinations of both types
of therapies.

We are advancing combinations of immune-cell targeted therapies e.g.
cancer vaccines, oncolytic viruses and T-cell engagers, as well as
immunogenic cell death inducers such as our SMAC mimetic with BI 754091,
a PD-1 checkpoint inhibitor.

In cancer cell directed projects, Boehringer Ingelheim’s oncology
research portfolio includes more than 10 clinical-stage assets. We are
working on new drug candidates in pathways such as KRAS, WNT and p53,
and will move towards clinical trials for many of these in the next
12-24 months.

Central Nervous System

In CNS, Boehringer Ingelheim has expanded its PDE9 inhibition research
programs to the prevention of relapse in schizophrenia and also in the
prevention of first episode psychosis.

Boehringer Ingelheim’s research approach in CNS is taking a courageous
“against the current” approach. The focus is on understanding how
underlying malfunctions in brain circuitry manifest in specific symptoms
and traits of mental illnesses. This is key to going beyond the current
disease classifications which do not reflect the underlying disease
mechanisms.

Boehringer Ingelheim investigates a range of mental disorders such as
schizophrenia, Alzheimer’s disease and depression.

Fibrosis (Respiratory and Cardiometabolic Diseases)

Based on the pathophysiological and mechanistic parallels of fibrotic
diseases, Boehringer Ingelheim is investigating its compound nintedanib
in a wide spectrum of fibrosing Interstitial Lung Diseases (ILDs).

Two Phase III clinical trials are exploring the efficacy and safety of
nintedanib (OFEV®) in Systemic Sclerosis ILD (SSc-ILD) and
Progressive Fibrosing ILD (PF-ILD). The SENSCIS study has completed
enrolment and may end in December 2018. The INBUILD study is likely to
complete enrolment in Q2 2018.

In NASH, another fibrotic disease affecting the liver, Boehringer
Ingelheim applies its deep understanding of the metabolic, inflammatory
and fibrotic components of the disease and is investigating a
frontrunner compound, an AOC3 inhibitor, in a Phase II clinical trial.

Cardiometabolic Diseases

In Cardiometabolic diseases, Boehringer Ingelheim is building on the
strength of the results of the EMPA-REG OUTCOME® trial to
explore the potential benefits of empagliflozin (JARDIANCE®1)
beyond diabetes. Boehringer Ingelheim is investigating the potential of
empagliflozin to protect patients with and without diabetes from the
risk of chronic kidney disease and chronic heart failure.

Phase III studies are underway investigating the effects of
empagliflozin in patients with Chronic Kidney Disease (CKD) and in
patients with Chronic Heart Failure (CHF). The EMPA-KIDNEY and EMPEROR
HEART FAILURE studies are expected to read out between 2019 and 2020.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the
research-driven pharmaceutical company Boehringer Ingelheim. The focus
in doing so is on diseases for which no satisfactory treatment option
exists to date. The company therefore concentrates on developing
innovative therapies that can extend patients’ lives. In animal health,
Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is
one of the pharmaceutical industry’s top 20 companies. Some 50,000
employees create value through innovation daily for the three business
areas human pharmaceuticals, animal health and biopharmaceuticals. In
2017, Boehringer Ingelheim achieved net sales of nearly
18.1 billion euros. R&D expenditure, exceeding three billion euros,
corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and
focuses on long-term success, rather than short-term profit. The company
therefore aims at organic growth from its own resources with
simultaneous openness to partnerships and strategic alliances in
research. In everything it does, Boehringer Ingelheim naturally adopts
responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com

1 Jardiance® is jointly marketed by Boehringer
Ingelheim and Eli Lilly and Company.

Contacts

Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head
of Communications, Innovation Unit
Media + PR
Phone: +49 6132
77-90815
press@boehringer-ingelheim.com

Source: Boehringer Ingelheim

Étiquettes :